Researchers have used a membrane-localizing technology to generate a novel class of thrombin inhibitors, named thrombalexins (TLNs), that bind to cell surfaces and could potentially be used to prevent acute antibody-mediated thrombosis in donor organs. In a rat renal allograft model of hyperacute antibody-mediated rejection, perfusion of donor kidneys with TLN-1 before transplantation substantially reduced intragraft thrombosis and increased graft survival.
Karegli, J. et al. Thrombalexins: cell-localized inhibition of thrombin and its effects in a model of high-risk renal transplantation. Am. J. Transplant. http://dx.doi.org/10.1111/ajt.13951 (2016)
About this article
Cite this article
Carney, E. Thrombalexins protect renal allografts. Nat Rev Nephrol 12, 510 (2016). https://doi.org/10.1038/nrneph.2016.117